Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: Brett Fleischman who wrote (60757)	3/10/1999 9:06:00 PM
From: hoffy	Respond to of 119973

IMCL looks to be huge. The float is 17 million and if the CNBC piece is good and I think it will be this stock will get to the mid 20's easily. They have so much good news recently to talk about. First of all is the promise of their drug going into phase 3 testing. Next is the $5 million in milestone payment from Merck. This will take the pressure off of earnings for a while. Look at the projected revenues and earnings in the Below quoted article. Very impressive. ==================================================== Calculating that multiple for ImClone, McCamant says he "finds it hard to believe" sales of C225 will be less than $200 million by 2002, and possibly as high as $500 million. Using the midpoint multiple of 7.5 times revenue, the analyst sees a range of between $1.5 billion and $3.75 billion in ImClone's market capitalization. That nets to a share price range of $60 - $150, a dramatic improvement over the current price